New DelhiThe recruitment of volunteers for the Phase II of the three clinical trials of the anti-Covid-19 vaccine Kovovax among children aged two to 17 years at the Hamdard Institute of Medical Sciences and Research began on Sunday. According to official sources, the test will take place at 10 locations and will involve 920 children, including 460-460 children in the 12-17 and 2-11 age groups.
Testing allowed with certain conditions Drug company Zydus Cadila’s indigenously developed needleless COVID-19 vaccine Zycov-D has received approval from the drug regulator for emergency use, making it the first vaccine in the country to be administered in the age group of 12-18 years Is. India’s drug regulator in July asked the Serum Institute of India (SII) to conduct a phase II trial of Kovovax on children aged two to 17 years, based on the recommendations of the Subject Expert Committee (CEC) on COVID-19, with certain conditions. But was allowed.
Children’s vaccination required In an application submitted to the Drugs Controller General of India (DCGI), Prakash Kumar Singh, Director (Government and Regulatory Affairs) of SII and Prasad Kulkarni, director, had said that globally, all adults aged 18 years and above are being vaccinated. and thereafter the protection of this population against COVID-19 is ensured but children will remain a vulnerable group.
The third wave can affect He had said, ‘There have been reports of serious illness including death in vulnerable children. It has also been feared that the third wave of the epidemic in the country may affect children. “In the Phase II study out of a three-phase trial in India, more than 1,400 participants have received at least the first dose of the vaccine, with no safety concerns reported so far,” the application said.
[Attribution to NBT]